Pausing spinal-fluid chemotherapy for EGFR-positive lung cancer that has spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests whether pausing and restarting chemotherapy given directly into the spinal fluid helps people with EGFR-positive lung cancer that has spread to the brain and spinal cord lining. The goal is to see if this approach reduces side effects while keeping the cancer under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your lung cancer has an EGFR mutation (a specific genetic change).
- Cancer cells have been found in the fluid around your brain and spinal cord (called leptomeningeal metastasis).
- Your liver, kidney, and blood function are within normal limits.
- You have no history of a serious nervous system disease.
- You have no severe blood disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted therapy (firmanertinib), a biologic drug that blocks blood vessel growth (bevacizumab), and a chemotherapy given into the spinal fluid (pemetrexed) for people with non-small cell lung cancer that has spread to the membranes around the brain (leptomeningeal metastasis). The goal is to see if this treatment helps control the cancer and improve symptoms.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
This trial tests a chemotherapy drug given directly into the spinal fluid for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). It may help when standard treatments have stopped working or caused too many side effects.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
Hear when a new Leptomeningeal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.